Milae Bioresources

At a glance

Milae Bioresources filed 14 disclosures in the last 12 months, including 1 5% holder. The most recent key filing was on Mar 12.

Revenue for 2025 was ₩67.6B, up 8.2% on 2024. It made an operating loss of ₩1.4B. Debt was 38% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩36.4B and operating profit of ₩1.1B.

The 2025 annual report lists 56 employees with an average tenure of 6.6 years and average pay of ₩44.6M, #1659 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩125M each on average. It paid no cash dividend for 2025. 김성진 and related parties held 50.69% at year end.

From the 2025 annual report

Staff: 56 (36 men, 20 women), of whom 6 on fixed-term contracts. Total pay for the year: ₩2.5B. Directors and auditors: 4, paid ₩250M in total.

No cash dividend was paid for 2025.

Largest shareholder

김성진 holds 48.69%; with 5 related parties the group holds 50.69% of common shares at year end.

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary